Optum Rx Takes Additional Steps To Lower The Cost Of Insulin; Beginning Jan. 1, 2024, Optum Rx Will Place Eight Preferred Insulin Products On Tier One Of Standard Commercial Formularies, Limiting Out-Of-Pocket Spend To $35 Or Less
Portfolio Pulse from Benzinga Newsdesk
Optum Rx, a pharmacy services company, is taking additional steps to make insulin more affordable. Starting from Jan. 1, 2024, it will place eight preferred insulin products on tier one of standard commercial formularies, limiting out-of-pocket spend to $35 or less. This move is part of Optum Rx's ongoing efforts to improve access and make critical medications more affordable. The products of three manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, will be added to tier one. Optum Rx also supported UnitedHealthcare in eliminating copays for consumers in group fully insured plans for insulin and other critical drugs.
November 09, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's insulin products will be added to tier one of Optum Rx's standard commercial formularies, potentially increasing sales.
The inclusion of Eli Lilly's insulin products in the tier one of Optum Rx's formularies could lead to increased sales as more consumers will have access to these products at a lower cost.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
Novo Nordisk's insulin products will be added to tier one of Optum Rx's standard commercial formularies, potentially increasing sales.
The inclusion of Novo Nordisk's insulin products in the tier one of Optum Rx's formularies could lead to increased sales as more consumers will have access to these products at a lower cost.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
Sanofi's insulin products will be added to tier one of Optum Rx's standard commercial formularies, potentially increasing sales.
The inclusion of Sanofi's insulin products in the tier one of Optum Rx's formularies could lead to increased sales as more consumers will have access to these products at a lower cost.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
UnitedHealthcare, supported by Optum Rx, has eliminated copays for consumers in group fully insured plans for insulin and other critical drugs, potentially increasing customer satisfaction and retention.
The elimination of copays for insulin and other critical drugs by UnitedHealthcare, supported by Optum Rx, could lead to increased customer satisfaction and retention.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75